CannaMore Biotechs Completes Phase 2a Trial for CBD Ulcerative Colitis Treatment

TEL AVIV, Israel, July 22, 2024 — CannaMore Biotechs, an Israeli clinical-stage company specializing in Cannabidiol (CBD) treatments, has successfully wrapped up its Phase 2a clinical trial. This study evaluated the safety and efficacy of a CBD-based enema formulation, IcBD-01, for patients suffering from Ulcerative Colitis (UC).

This open-label, single-arm trial aimed to evaluate the safety, tolerability, and effectiveness of IcBD-01 as a potential treatment for UC. Over a three-month period, 10 patients participated and completed the trial, which yielded promising results for most participants.

Key findings from the trial include:

- Achievement of Primary Endpoint: A significant reduction in Mayo scores was observed in a majority of patients, indicating decreased disease severity.
- Patient-Reported Outcomes (PRO): Most participants reported notable improvements in symptoms, such as reduced abdominal pain and an overall boost in well-being.
- Safety and Tolerability: IcBD-01 was well-tolerated among participants, with no major side effects noted, affirming the formulation’s safety profile.

The study was led by Prof. Timna Naftali, a gastroenterology expert at Meir Hospital in Kfar Saba, Israel. Conducted at leading Israeli medical facilities, Meir Hospital is part of Clalit Health Services, the world’s second-largest Health Maintenance Organization (HMO) and a collaborator with CannaMore through Mor Research Applications TTO.

Prof. Naftali expressed optimism about the results, saying, "The trial’s outcomes are very encouraging and endorse the potential of IcBD-01 as an effective UC treatment. We saw significant improvements in both clinical outcomes and patient-reported symptoms. This marks an important step forward in our pursuit of innovative CBD-based therapies. This treatment could offer a safe and effective solution for patients with ulcerative proctitis, an area with an unmet need for effective treatments."

Given these positive results, CannaMore Biotechs intends to progress to the next stage of clinical trials to further assess the long-term efficacy and safety of IcBD-01. Additionally, the company plans to explore immediate non-drug markets, such as medical cannabis, while continuing their drug research and development efforts aimed at securing FDA approval.

About CannaMore Biotechs Ltd.:
CannaMore Biotechs Ltd. focuses on the independent research and development of cannabinoid-based pharmaceuticals for various health conditions. Supported by a partnership with Mor Research Applications, CannaMore utilizes advanced research to develop innovative treatments for patients. As a clinical research platform with multiple projects, IcBD in colitis stands as their leading initiative, positioning CannaMore at the forefront of cannabinoid-based medical advancements.